News Lilly/Boehringer diabetes combos get cardio data boost Lilly/Boehringer gain further advantage in US diabetes market.
News Alnylam plunges after deaths in rare disease trial Biotech axes revusiran due to safety concerns.
News Patients may have quit statins after media row Coverage may have given "disproportional weight" to concerns over side effects.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.